A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Active, not recruiting · Phase 1, Phase 2 · NCT03899792
Conditions: Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
At a glance
- Research payments reported, 2025
- $273,146
- U.S. investigators named
- 10
- Sites paid
- 10
- Planned or actual enrollment
- 36
About the trial
- Sponsor
- Eli Lilly and Company (with Loxo Oncology, Inc.)
- Tested
- Selpercatinib (drug)
- Dates
- Started 2019-06-13; completion 2029-05
- Results posted
- Yes
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
From ClinicalTrials.gov, last updated 2026-01-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $273,146 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ramamoorthy Nagasubramanian, MD Pediatric Hematology & Oncology · Palo Alto, CA
- Fariba Navid, MD Pediatric Hematology & Oncology · Los Angeles, CA
- Steven G. Dubois, M.D. Pediatric Hematology & Oncology · Boston, MA
- Emily Greengard, M.D. Pediatric Hematology & Oncology · Minneapolis, MN
- Julia Glade Bender, MD Pediatric Hematology & Oncology · New York, NY
- Theodore W. Laetsch JR., MD Pediatrics · Philadelphia, PA
- Alberto S. Pappo, M.D. Pediatric Hematology & Oncology · Memphis, TN
- Stephanie L. Fetzko, M.D. Pediatric Hematology & Oncology · Houston, TX
- Tanya C. Watt, M.D. Pediatric Hematology & Oncology · Dallas, TX
- Douglas S. Hawkins Pediatric Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- St Jude Childrens Hospital $117,706
- Seattle Children's Hospital, WA $46,283
- Children's Hospital of Philadelphia, PA $30,846
- Children's Hosp of Los Angeles, CA $21,790
- Sloan Kettering Inst for Cancer Research $19,680
- Regents of the University of Minnesota $11,710
- Baylor College of Medicine $8,327
- The University of Texas $7,146
- Dana Farber PArtners Cancer Care Inc $6,908
- Nemours Children's Hospital, Delaware, DE $2,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.